Engineering Future Medicines
GEN-Y combines cutting-edge protein engineering, AI-based modelling and advanced automation to develop best-in-class antibodies for diagnostics and therapies
GEN-Y Biologics has an exciting pipeline of development opportunities in infectious illnesses and cancer. The initial focus is on the dengue portfolio – representing a new paradigm in treatment of this infectious tropical disease.
Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker sales.
A fast, sensitive and specific laboratory test for Immunity to covid-19 infection
GEN-Y’s ImTracker COVID Viral Variant Neutralization Test is a serological enzyme-linked immunosorbent assay (ELISA) that identifies neutralizing antibodies that are able to block infection by the latest viral variants that cause Covid. The ImTracker test has been granted the European Conformity CE Mark, and is available now as an In Vitro Diagnostic (IVD).
A wide range of RBD viral variants are available for sale individually, including the latest Omicron sub-variants XBB and XBB.1.5. See Order Products Section.
GEN-Y Biologics Dengue Treatment Featured on Channel News Asia
Kill the dengue virus in 6 hours instead of 2 weeks? Associate Professor Paul MacAry and his team from the Immunology Translational Research Programme at the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine) isolated a human antibody after screening “literally hundreds of millions” of antibodies derived from individuals who had recovered from dengue serotype 1. See the video of the interview with him.